Effectiveness of the Combined Evaluation of KLK3 Genetics and Free-to-Total Prostate Specific Antigen Ratio for Prostate Cancer Diagnosis
Abstract
Purpose:
Of serum prostate specific antigen variability 40% depends on inherited factors. We ascertained whether the knowledge of KLK3 genetics would enhance prostate specific antigen diagnostic performance in patients with clinical suspicion of prostate cancer.
Materials and Methods:
We studied 1,058 men who consecutively underwent prostate biopsy for clinical suspicion of prostate cancer. At histology prostate cancer was present in 401 cases and absent in 657. Serum total prostate specific antigen and the free-to-total prostate specific antigen ratio were determined. Four polymorphisms of the KLK3 gene (rs2569733, rs2739448, rs925013 and rs2735839) and 1 polymorphism of the SRD5A2 gene (rs523349) were studied. The influence of genetics on prostate specific antigen variability was evaluated by multivariate linear regression analysis. The performance of total prostate specific antigen and the free-to-total prostate specific antigen ratio alone or combined with a genetically based patient classification were defined by ROC curve analyses.
Results:
For prostate cancer diagnosis the free-to-total prostate specific antigen ratio index alone (cutoff 11%) was superior to total prostate specific antigen (cutoff 4 ng/ml) and to free-to-total prostate specific antigen ratio reflex testing (positive predictive value 61%, 43% and 54%, respectively). Prostate specific antigen correlated with KLK3 genetics (rs2735839 polymorphism p = 0.001, and rs2569733, rs2739448 and rs925013 haplotype combination p = 0.003). In patients with different KLK3 genetics 2 optimal free-to-total prostate specific antigen ratio cutoffs (11% and 14.5%) were found. For free-to-total prostate specific antigen ratio values between 11% and 14.5% the prostate cancer probability ranged from 30.0% to 47.4% according to patient genetics.
Conclusions:
The free-to-total prostate specific antigen ratio is superior to total prostate specific antigen for prostate cancer diagnosis, independent of total prostate specific antigen results. Free-to-total prostate specific antigen ratio findings below 11% are positively associated with prostate cancer and those above 14.5% are negatively associated with prostate cancer, while the interpretation of those between 11% and 14.5% is improved by patient KLK3 genetic analysis.
References
- 1 : Mortality results from a randomized prostate-cancer screening trial. N Engl J Med2009; 360: 1310. Google Scholar
- 2 : Screening and prostate-cancer mortality in a randomized European study. N Engl J Med2009; 360: 1320. Google Scholar
- 3 : Screening for prostate cancer: an updated Cochrane systematic review. BJU Int2011; 107: 882. Google Scholar
- 4 : Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nat Rev Cancer2008; 8: 268. Google Scholar
- 5 : Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2–10 ng/ml: systematic review and meta-analysis. Eur Urol2005; 48: 386. Google Scholar
- 6 : Total PSA, free PSA/total PSA ratio, and molecular PSA detection in prostate cancer: which is clinically effective and when?. Urology2000; 55: 710. Google Scholar
- 7 : Heritability of cardiovascular and personality traits in 6,148 Sardinians. PLoS Genet2006; 2: e132. Google Scholar
- 8 : Multiple newly identified loci associated with prostate cancer susceptibility. Nat Genet2008; 40: 316. Google Scholar
- 9 : Association of KLK3 (PSA) genetic variants with prostate cancer risk and PSA levels. Carcinogenesis2011; 32: 853. Google Scholar
- 10 : Fine mapping the KLK3 locus on chromosome 19q13.33 associated with prostate cancer susceptibility and PSA levels. Hum Genet2011; 129: 675. Google Scholar
- 11 : Identification of a novel prostate cancer susceptibility variant in the KLK3 gene transcript. Hum Genet2011; 129: 687. Google Scholar
- 12 : Variation in KLK genes, prostate-specific antigen and risk of prostate cancer. Nat Genet2008; 40: 1032. Google Scholar
- 13 : Association of prostate cancer risk variants with clinicopathologic characteristics of the disease. Clin Cancer Res2008; 14: 5819. Google Scholar
- 14 : Association of reported prostate cancer risk alleles with PSA levels among men without a diagnosis of prostate cancer. Prostate2009; 69: 419. Google Scholar
- 15 : Characterizing associations and SNP-environment interactions for GWAS-identified prostate cancer risk markers–results from BPC3. PLoS One2011; 6: e17142. Google Scholar
- 16 : Association between genetic polymorphisms in the prostate-specific antigen gene promoter and serum prostate-specific antigen levels. J Natl Cancer Inst2003; 95: 1044. Google Scholar
- 17 : Molecular epidemiology of prostate cancer: androgens and polymorphisms in androgen-related genes. Eur J Endocrinol2003; 149: 469. Google Scholar
- 18 : A prevalent missense substitution that modulates activity of prostatic steroid 5alpha-reductase. Cancer Res1997; 57: 1020. Google Scholar
- 19 : Association of polymorphisms within androgen receptor, 5alpha-reductase, and PSA genes with prostate volume, clinical parameters, and endocrine status in elderly men. Prostate2002; 52: 130. Google Scholar
- 20 : The SRD5A2 V89L polymorphism is associated with severity of disease in men with early onset prostate cancer. Prostate2008; 68: 1798. Google Scholar
- 21 : SRD5A polymorphisms and biochemical failure after radical prostatectomy. Eur Urol2011; 60: 1226. Google Scholar
- 22 : Blood biomarker levels to aid discovery of cancer-related single-nucleotide polymorphisms: kallikreins and prostate cancer. Cancer Prev Res2010; 3: 611. Google Scholar
- 23 : EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. European Association of Urology. Eur Urol2011; 59: 61. Google Scholar
- 24 : Individual and cumulative effect of prostate cancer risk-associated variants on clinicopathologic variables in 5,895 prostate cancer patients. Prostate2009; 69: 1195. Google Scholar
- 25 : Effect of verification bias on screening for prostate cancer by measurement of prostate-specific antigen. N Engl J Med2003; 349: 335. Google Scholar
- 26 : Genetic correction of PSA values using sequence variants associated with PSA levels. Sci Transl Med2010; 2. 62ra92. Google Scholar
